Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition

BACKGROUND: Metformin slows tumor growth and progression in vitro, and in combination with chemoradiotherapy, resulted in high overall survival in patients with head and neck cancer squamous cell carcinoma (HNSCC) in our phase 1 clinical trial (NCT02325401). Metformin is also postulated to activate...

Descripción completa

Detalles Bibliográficos
Autores principales: Crist, McKenzie, Yaniv, Benyamin, Palackdharry, Sarah, Lehn, Maria A, Medvedovic, Mario, Stone, Timothy, Gulati, Shuchi, Karivedu, Vidhya, Borchers, Michael, Fuhrman, Bethany, Crago, Audrey, Curry, Joseph, Martinez-Outschoorn, Ubaldo, Takiar, Vinita, Wise-Draper, Trisha M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639146/
https://www.ncbi.nlm.nih.gov/pubmed/36328378
http://dx.doi.org/10.1136/jitc-2022-005632

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639146/
https://www.ncbi.nlm.nih.gov/pubmed/36328378
http://dx.doi.org/10.1136/jitc-2022-005632

Ejemplares similares